U C Broedl
Overview
Explore the profile of U C Broedl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
742
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salsali A, Kim G, Woerle H, Broedl U, Hantel S
Diabetes Obes Metab
. 2016 Jul;
18(10):1034-40.
PMID: 27376831
Aim: To assess the effect of empagliflozin on cardiovascular (CV) risk in patients with type 2 diabetes (T2DM) through a meta-analysis of data from eight placebo-controlled trials. Methods: Data were...
2.
Mondick J, Riggs M, Sasaki T, Sarashina A, Broedl U, Retlich S
Diabetes Obes Metab
. 2015 Oct;
18(3):241-8.
PMID: 26511213
Aims: To quantify the effect of the sodium-glucose co-transporter 2 inhibitor, empagliflozin, on renal glucose reabsorption in patients with type 2 diabetes, and to evaluate covariate effects, using a mechanistic...
3.
Chilton R, Tikkanen I, Cannon C, Crowe S, Woerle H, Broedl U, et al.
Diabetes Obes Metab
. 2015 Sep;
17(12):1180-93.
PMID: 26343814
Aims: To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM). Methods: We conducted...
4.
Pieber T, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen O, et al.
Diabetes Obes Metab
. 2015 Jun;
17(10):928-35.
PMID: 26080652
Aims: To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes. Methods: A total of 75 patients with glycated haemoglobin (HbA1c)...
5.
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl U, Woerle H
Diabetes Obes Metab
. 2015 Jun;
17(10):936-48.
PMID: 26040302
Aims: To investigate the efficacy and tolerability of empagliflozin added to basal insulin-treated type 2 diabetes. Methods: Patients inadequately controlled [glycated haemoglobin (HbA1c) >7 to ≤10% (>53 to ≤86 mmol/mol)]...
6.
Merker L, Haring H, Christiansen A, Roux F, Salsali A, Kim G, et al.
Diabet Med
. 2015 Jun;
32(12):1555-67.
PMID: 26031566
Aims: To investigate the long-term efficacy and safety of empagliflozin as add-on to metformin in people with Type 2 diabetes. Methods: Of 637 participants treated with empagliflozin 10 mg, empagliflozin...
7.
Ross S, Thamer C, Cescutti J, Meinicke T, Woerle H, Broedl U
Diabetes Obes Metab
. 2015 Apr;
17(7):699-702.
PMID: 25827441
Patients with type 2 diabetes mellitus (T2DM) with a glycated haemoglobin (HbA1c) level ≥7 and ≤10% were randomized to receive empagliflozin 12.5 mg twice daily (n = 219), 25 mg...
8.
Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, et al.
Diabetes Obes Metab
. 2015 Mar;
17(7):665-74.
PMID: 25772548
Aims: To evaluate the safety and efficacy of empagliflozin for 52 weeks as add-on to one other oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus (T2DM). Methods:...
9.
Kovacs C, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle H, et al.
Diabetes Obes Metab
. 2013 Aug;
16(2):147-58.
PMID: 23906415
Aims: This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM). Methods: Patients with HbA1c ≥7 and ≤10%...
10.
Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl U, et al.
Diabetes Obes Metab
. 2013 Jul;
16(2):118-23.
PMID: 23859534
Aims: This open-label, parallel-group study investigated the effect of various degrees of hepatic impairment on the pharmacokinetics, safety and tolerability of the sodium glucose cotransporter 2 inhibitor empagliflozin. Methods: Thirty-six...